News Oligomerix Announces Key Organizational Changes in Transition to Clinically Focused Company July 20, 2022 By vera This article is sourced from an external publication. Read the original → ← PreviousOligomerix Announces Series B Extension Raise of $2.7 Million to Support Phase 1 Clinical DevelopmentNext →Oligomerix Awarded $3.35M from NIH to Support Clinical Development of Tau-Targeting Alzheimer’s Disease Therapy
